Company Overview
MAIA Biotechnology, Inc. operates as an immuno-oncology company dedicated to the development and commercialization of drugs featuring novel mechanisms of action intended to improve and extend the lives of patients with cancer. The company functions within the broader Healthcare sector and specifically targets the Biotechnology industry, a field characterized by high-risk research and development aimed at creating transformative medical therapies. As of the latest available data, the company maintains a market capitalization of $79.48M, while its annual revenue and total employee count are not disclosed in the provided financial records. This market cap figure indicates that MAIA is a small-cap entity, suggesting it operates with limited resources compared to large-cap pharmaceutical peers and likely requires significant capital allocation to advance its lead program, THIO, a potential cancer telomere-targeting therapy. The absence of reported revenue data further contextualizes the company's position as an early-stage biotechnology firm that has not yet achieved commercial scale or profitability from its drug portfolio.
Financial Health
The company reports a Net Income of $-22,396,172 over the trailing twelve months, while Revenue and EBITDA figures are not available for disclosure. The substantial gap between the reported net income loss and the unreported revenue implies that the company's cost structure is heavily weighted toward research and development expenses rather than commercial operating costs. Free Cash Flow stands at $-11,023,186, indicating that the company is currently burning cash to fund its operations and clinical trials, which limits its immediate financial flexibility without external financing. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure typical for pre-revenue biotechnology firms where costs are deducted before any revenue is recognized, resulting in zero percentage calculations in the financial model. The company holds a Cash balance of $8.66M, whereas Debt is listed as N/A, and the Debt to Equity ratio is also N/A; however, the presence of cash without disclosed debt suggests a conservative balance sheet structure reliant on equity financing rather than leverage. The Current Ratio is 1.66, which indicates that the company possesses sufficient liquid assets to cover its short-term obligations, providing a buffer against immediate liquidity pressures despite the negative free cash flow. Return on Equity is -745.2% and Return on Assets is -152.8%, metrics that reveal management is currently deploying capital to generate losses rather than positive returns, a common characteristic in the early development phases of biotechnology companies where asset bases are often inflated by intangible research assets.
Valuation Assessment
The Trailing Twelve Months P/E Ratio is N/A due to the lack of net income, while the Forward P/E is 0.49, a divergence that implies the market is pricing in a future earnings recovery or is utilizing a non-GAAP metric for forward projections despite the current unprofitability. The Price to Book ratio is 21.13, indicating that the market values the company at a significant premium over its book value, likely reflecting the high potential value assigned to its intellectual property and pipeline assets rather than its tangible assets. Price to Sales and EV/EBITDA metrics are both N/A, suggesting that traditional valuation multiples are not applicable or disclosed, which forces investors to rely on market cap and cash burn rates to assess value. The stock has traded between a 52-Week High of $3.19 and a 52-Week Low of $0.87, and without a specific current price, the exact percentage distance from the high cannot be calculated, but the wide range demonstrates significant price volatility typical of small-cap biotech stocks. The Beta is -0.02, a negative value that technically suggests an inverse correlation to the broader market or a statistical anomaly in the data source, as beta values are rarely negative for equities, yet it implies that the stock's price movements do not follow the standard positive correlation pattern of the broader market.
Growth & Income
Revenue Growth and Earnings Growth rates are both N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, though the negative net income confirms the company is not currently generating profits to fund expansion. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which indicates that the firm reinvests all available capital and potential earnings back into its research and development efforts rather than distributing income to shareholders. This reinvestment strategy is standard for immuno-oncology companies in the development phase, where preserving cash for clinical trials is prioritized over income distribution. Overall, the growth and income profile is defined by zero current income generation and a reliance on future product approvals to drive capital appreciation, rather than dividend income or consistent revenue expansion.